AKT1 and Hyperglycemia: Although ATP-competitive AKT inhibitors such as AZD5363 or GSK690693 have shown encouraging preclinical results, this compound class shows significant clinical toxicity (hyperglycemia, rash, liver toxicity) due to limited selectivity on ATP-binding site recognition in AKT proteins versus other protein kinases [7,10,21].